



Congenital Disorders of Glycosylation

Precision Panel



Overview

Congenital Disorders of Glycosylation (CDG) are a group of rapidly expanding metabolic disorders that arise due to abnormal protein or lipid glycosylation. There are difficulties trying to diagnose them because they broadly affect many organs and functions, demonstrating a clinical heterogeneity. These phenotypically diverse disorders present as clinical syndromes affecting multiple systems including the central nervous system, muscle function, transport, regulation, immunity, endocrine system, and coagulation. Over 150 different CDGs have been and those affecting N-glycosylation are the most common type.

The Igenomix Congenital Disorders of Glycosylation Precision Panel can be used to make an accurate and directed diagnosis ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved.

Indications

The Igenomix Congenital Disorders of Glycosylation Precision Panel is indicated for those patients with a clinical suspicion or diagnosis with or without the following manifestations:

- Low muscle tone or floppiness
- Failure to thrive
- Gross developmental delay
- Liver disease
- Abnormal bleeding or blood clotting
- Misaligned or crossed eyes
- Seizures
- Stroke-like episodes

Clinical Utility

The clinical utility of this panel is:

- The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient.
- Early initiation of treatment with a multidisciplinary team in the form of nutritional therapy, transplantation, activated sugars, gene therapy and pharmacological chaperones.





- Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance.
- Improvement of delineation of genotype-phenotype correlation given the clinical and genetically heterogenous profile of CDGs.

Genes & Diseases

| GENE | OMIM DISEASES | INHERITANCE* | % GENE COVERAGE (20X) | HGMD** |
|----------|---|--------------|-----------------------------|----------|
| ALG1 | Congenital Disorder Of Glycosylation | AR | 100 | 46 of 46 |
| ALG11 | Congenital Disorder Of Glycosylation | AR | 99.91 | 19 of 19 |
| ALG12 | Congenital Disorder Of Glycosylation | AR | 100 | 17 of 17 |
| ALG13 | Epileptic Encephalopathy, Intellectual Disability | X,XR,XD,G | 99.62 | - |
| ALG14 | Myasthenic Syndrome With Glycosylation Defect | AR | 99.99 | 7 of 7 |
| ALG2 | Congenital Disorder Of Glycosylation, Myasthenic Syndrome | AR | 99.61 | 7 of 7 |
| ALG3 | Congenital Disorder Of Glycosylation | AR | 99.2 | 25 of 25 |
| ALG6 | Congenital Disorder Of Glycosylation | AR | 99.91 | 24 of 24 |
| ALG8 | Congenital Disorder Of Glycosylation, Polycystic Liver Disease | AD,AR | 99.5 | 22 of 22 |
| ALG9 | Congenital Disorder Of Glycosylation, Polycystic Kidney Disease | AR | 99.99 | 6 of 6 |
| ATP6AP2 | Congenital Disorder Of Glycosylation, Mental Retardation, Parkinsonism With Spasticity | X,XR,G | 100 | - |
| ATP6V0A2 | Cutis Laxa, Wrinkly Skin Syndrome, Congenital Disorder Of Glycosylation | AR | 99.99 | 55 of 55 |
| ATP6V1A | Cutis Laxa, Epileptic Encephalopathy | AD,AR | 99.98 | 9 of 9 |
| ATP6V1E1 | Cutis Laxa, Congenital Disorder Of Glycosylation | AR | 100 | 2 of 2 |
| B4GALT1 | Congenital Disorder Of Glycosylation | AR | 99.97 | 3 of 3 |
| CAD | Epileptic Encephalopathy | AR | 100 | 12 of 12 |
| CCDC115 | Congenital Disorder Of Glycosylation | AR | 100 | 4 of 4 |
| COG1 | Congenital Disorder Of Glycosylation | AR | 99.91 | 3 of 3 |
| COG2 | Congenital Disorder Of Glycosylation | AR | 96.97 | 4 of 4 |
| COG4 | Congenital Disorder Of Glycosylation, Saul-Wilson Syndrome | AD,AR | 100 | 5 of 5 |
| COG5 | Congenital Disorder Of Glycosylation | AR | 100 | 19 of 19 |
| COG6 | Congenital Disorder Of Glycosylation, Shaheen Syndrome, Hypohidrosis- Enamel Hypoplasia-Palmoplantar Keratoderma-Intellectual Disability Syndrome | AR | 100 | 13 of 13 |
| COG7 | Congenital Disorder Of Glycosylation | AR | 99.94 | 6 of 6 |
| COG8 | Congenital Disorder Of Glycosylation | AR | 100 | 8 of 8 |
| CRPPA | Limb-Girdle Muscular Dystrophy, Walker-Warburg Syndrome | AR | 97.69 | - |
| DAG1 | Limb-Girdle Muscular Dystrophy, Muscle-Eye-Brain Disease, Walker-Warburg Syndrome | AR | 99.98 | 9 of 9 |
| DDOST | Congenital Disorder Of Glycosylation | AR | 100 | 2 of 2 |
| DOLK | Congenital Disorder Of Glycosylation, Dilated Cardiomyopathy | AR | 99.98 | 13 of 13 |
| DPAGT1 | Congenital Disorder Of Glycosylation, Myasthenic Syndrome | AR | 100 | 41 of 41 |
| DPM1 | Congenital Disorder Of Glycosylation | AR | 97.25 | 9 of 9 |
| DPM2 | Congenital Disorder Of Glycosylation, Congenital Muscular Dystrophy With Intellectual Disability And Severe Epilepsy | AR | 99.87 | 2 of 2 |
| DPM3 | Congenital Disorder Of Glycosylation, Lind-Girdle Muscular Dystrophy | AR | 100 | 4 of 4 |
| FCSK | Congenital Disorder Of Glycosylation | AR | 97.99 | - |
| | | | | |





| FKRP | Limb-Girdle Muscular Dystrophy, Muscle-Eye-Brain Disease, Walker-Warburg Syndrome | AR | 99.9 | 157 of 157 |
|---------|--|--------|-------|------------|
| FKTN | Cardiomyopathy, Lind-Girdle Muscular Dystrophy, Dilated Cardiomyopathy, Muscle-Eye-Brain Disease, Walker- Warburg Syndrome | AR | 98 | 54 of 56 |
| FUT8 | Congenital Disorder Of Glycosylation | AR | 99.73 | 4 of 4 |
| GALNT2 | Congenital Disorder Of Glycosylation | AR | 99.7 | 7 of 7 |
| GFPT1 | Myasthenic Syndrome, Limb-Girdle Muscular Dystrophy | AR | 100 | 57 of 57 |
| GMPPB | Limb-Girdle Muscular Dystrophy, Myasthenic Syndrome, Muscle-Eye-Brain Disease | AR | 99.95 | 53 of 53 |
| LARGE1 | Limb-Girdle Muscular Dystrophy, Muscle-Eye-Brain Disease, Walker-Warburg Syndrome | AR | 100 | - |
| MAGT1 | Congenital Disorder Of Glycosylation, Immunodeficiency, Neoplasia | X,XR,G | 100 | - |
| MAN1B1 | Mental Retardation, Congenital Disorder Of Glycosylation | AR | 99.97 | 29 of 30 |
| MGAT2 | Congenital Disorder Of Glycosylation | AR | 97.19 | 5 of 5 |
| MOGS | Congenital Disorder Of Glycosylation | AR | 100 | 10 of 10 |
| MPDU1 | Congenital Disorder Of Glycosylation | AR | 100 | 7 of 7 |
| MPI | Congenital Disorder Of Glycosylation | AR | 100 | 20 of 20 |
| NGLY1 | Congenital Disorder Of Glycosylation, Alacrimia-Choreoathetosis-Liver Dysfunction Syndrome | AR | 99.8 | 28 of 28 |
| NUS1 | Congenital Disorder Of Glycosylation, Mental Retardation, Undetermined Early- Onset Epileptic Encephalopathy | AD,AR | 99.62 | 22 of 23 |
| PGM1 | Congenital Disorder Of Glycosylation | AR | 99.96 | 38 of 40 |
| PGM3 | Immunodeficiency | AR | 99.99 | 17 of 17 |
| PIGG | Mental Retardation, Wolf-Hirschhorn Syndorme | AR | 99.86 | 6 of 6 |
| PIGL | Zunich Neuroectodermal Syndrome, Chime Syndrome, Hyperphosphatasia- Intellectual Disability Syndrome | AR | 86 | 11 of 13 |
| PIGN | Fryns Syndrome, Multiple Congenital Anomalies-Hypotonia-Seizures Syndrome | AR | 93.97 | 36 of 39 |
| PIGT | Multiple Congenital Anomalies-Hypotonia-Seizures Syndrome, Hemoglobinuria | AD,AR | 100 | 15 of 15 |
| PMM2 | Congenital Disorder Of Glycosylation | AR | 100 | 127 of 129 |
| POMGNT1 | Limb-Girdle Muscular Dystrophy, Retinitis Pigmentosa, Muscle-Eye-Brain Disease, Walker-Warburg Syndrome | AR | 99.91 | 82 of 83 |
| POMK | Limb-Girdle Muscular Dystrophy, Walker-Warburg Syndrome | AR | 99.99 | 8 of 8 |
| POMT1 | Limb-Girdle Muscular Dystrophy, Muscle-Eye-Brain Disease, Walker-Warburg Syndrome | AR | 100 | 105 of 105 |
| POMT2 | Limb-Girdle Muscular Dystrophy, Muscle-Eye-Brain Disease, Walker-Warburg Syndrome | AR | 100 | 74 of 74 |
| RFT1 | Congenital Disorder Of Glycosylation | AR | 99.98 | 18 of 18 |
| SLC35A1 | Congenital Disorder Of Glycosylation | AR | 100 | 6 of 6 |
| SLC35A2 | Congenital Disorder Of Glycosylation | X,XD,G | 99.97 | - |
| SLC35C1 | Congenital Disorder Of Glycosylation | AR | 99.73 | 8 of 8 |
| SLC39A8 | Congenital Disorder Of Glycosylation | AR | 99.89 | 7 of 7 |
| SRD5A3 | Congenital Disorder Of Glycosylation, Kahrizi Syndrome | AR | 100 | 15 of 15 |
| SSR4 | Congenital Disorder Of Glycosylation | X,XR,G | 100 | - |
| STT3A | Congenital Disorder Of Glycosylation | AR | 99.95 | 4 of 4 |
| STT3B | Congenital Disorder Of Glycosylation | AR | 98.71 | 5 of 5 |
| TMEM165 | Congenital Disorder Of Glycosylation | AR | 93.69 | 4 of 5 |
| TMEM199 | Congenital Disorder Of Glycosylation | AR | 100 | 5 of 5 |

^{*}Inheritance: AD: Autosomal Dominant; AR: Autosomal Recessive; X: X linked; XLR: X linked Recessive; Mi: Mitochondrial; Mu: Multifactorial.
**Number of clinically relevant mutations according to HGMD





Methodology





Call +34 963 905 310 or send an email to supportspain@igenomix.com for any of the following objectives:

- Get more information about the test.
- Request your kit.
- Request a pick up of the kit after collecting the sample.

References

- Ng, B. G., & Freeze, H. H. (2018). Perspectives on Glycosylation and Its Congenital Disorders. Trends in genetics: TIG, 34(6), 466–476. https://doi.org/10.1016/j.tig.2018.03.002
- Scott, K., Gadomski, T., Kozicz, T., & Morava, E. (2014). Congenital disorders of glycosylation: new defects and still counting. *Journal of inherited metabolic disease*, 37(4), 609–617. https://doi.org/10.1007/s10545-014-9720-9
- 3. Verheijen, J., Tahata, S., Kozicz, T., Witters, P., & Morava, E. (2020). Therapeutic approaches in Congenital Disorders of Glycosylation (CDG) involving N-linked glycosylation: an update. *Genetics in medicine : official journal of the American College of Medical Genetics*, 22(2), 268–279. https://doi.org/10.1038/s41436-019-0647-2
- Bogdańska, A., & Tylki-Szymańska, A. (2020). Wrodzone zaburzenia glikozylacji białek stale powiększająca się grupa chorób metabolicznych [Congenital disorders of glycosylation - constantly growing group of metabolic diseases]. Postepy biochemii, 66(3), 213– 228. https://doi.org/10.18388/pb.2020_345
- Gilfix B. M. (2019). Congenital disorders of glycosylation and the challenge of rare diseases. Human mutation, 40(8), 1010–1012. https://doi.org/10.1002/humu.23829
- 6. Jaeken J. (2013). Congenital disorders of glycosylation. *Handbook of clinical neurology, 113,* 1737–1743. https://doi.org/10.1016/B978-0-444-59565-2.00044-7